Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Sino Biopharm Acquires LaNova Medicines in $951 Million Deal, Bolstering Cancer Drug Pipeline

In a significant move that reshapes the landscape of cancer drug development, Shanghai-based LaNova Medicines has agreed to be acquired by fellow Chinese company Sino Biopharmaceutical in a deal worth up to $951 million. This acquisition, announced on Tuesday, brings together two key players in the rapidly evolving Chinese biotech sector and has implications for several major Western pharmaceutical companies.

NoahAI News7/17/2025

Pharmaceutical Industry Faces Widespread Layoffs and Restructuring Amid Market Challenges

The pharmaceutical and biotech sectors are experiencing a wave of workforce reductions and strategic realignments as companies grapple with financial pressures, pipeline setbacks, and shifting market dynamics. Recent months have seen numerous firms announce significant layoffs and organizational changes in efforts to cut costs and refocus resources on key priorities.

NoahAI News7/17/2025

J&J Surpasses $15 Billion in Quarterly Pharmaceutical Sales, Offsetting Stelara Decline

Johnson & Johnson (J&J) has reported a record-breaking quarter for its pharmaceutical division, with sales exceeding $15 billion for the first time. This milestone comes despite the loss of market exclusivity for Stelara, previously one of the company's top-selling drugs. The strong performance, particularly in oncology, has led J&J to raise its operational growth expectations for 2025.

NoahAI News7/17/2025

Carlsmed Aims for $100M+ IPO, Advancing Personalized Spine Surgery with AI and 3D Printing

Carlsmed, a pioneering artificial intelligence-powered spine surgery developer, has announced plans for an initial public offering (IPO) on the Nasdaq, aiming to raise over $100 million. The company, which specializes in personalized fusion procedures using 3D-printed titanium spinal implants, is offering at least 6.7 million shares priced between $14 and $16 each.

NoahAI News7/17/2025

J&J's Electrophysiology Unit Rebounds Amid Fierce PFA Competition

Johnson & Johnson's electrophysiology division has shown signs of recovery in the second quarter of 2025, marking a significant turnaround from its previous decline. This resurgence comes as the company faces intense competition in the rapidly growing pulsed field ablation (PFA) market.

NoahAI News7/17/2025

Okyo Pharma's Urcosimod Shows Promise in Phase 2 Trial for Neuropathic Corneal Pain

Okyo Pharma has announced positive topline results from its phase 2 trial of urcosimod, a potential first-in-class treatment for neuropathic corneal pain (NCP). The London-based company's lead asset demonstrated significant pain reduction in patients with this mysterious eye condition, paving the way for further development and potential FDA approval.

NoahAI News7/17/2025

Zimmer Biomet Expands Robotics Portfolio with $177M Monogram Acquisition

Zimmer Biomet, a leading orthopedics company, has announced plans to acquire Monogram Technologies for approximately $177 million, significantly expanding its surgical robotics offerings. The deal, expected to close by the end of 2025, aims to bolster Zimmer Biomet's position in the rapidly evolving field of robotic-assisted orthopedic surgery.

NoahAI News7/17/2025

J&J's Innovative Medicines Drive Record $15B Quarter Despite Stelara Biosimilar Erosion

Johnson & Johnson (J&J) has demonstrated remarkable resilience in the face of biosimilar competition, posting a record-breaking $15 billion quarter for innovative medicines sales. This impressive performance comes as the company navigates the patent expiry of its blockbuster drug Stelara, showcasing J&J's ability to maintain growth through a diverse portfolio of cutting-edge therapies.

NoahAI News7/17/2025

Alphabet's SandboxAQ and iOncologi Partner to Develop mRNA Vaccine for Glioblastoma

Alphabet spinoff SandboxAQ has announced a groundbreaking collaboration with Florida-based biotech company iOncologi to develop a novel mRNA vaccine targeting glioblastoma, an aggressive form of brain cancer. The partnership, revealed on July 16, 2025, aims to leverage cutting-edge artificial intelligence and biologics technology to accelerate the development of a potentially life-saving treatment for one of the most challenging cancers.

NoahAI News7/17/2025

CVS Wins Major CalPERS Pharmacy Benefits Contract, Unseating UnitedHealth

CVS Health has secured a significant victory in the competitive pharmacy benefit manager (PBM) landscape, winning a lucrative contract with the California Public Employees' Retirement System (CalPERS). The five-year agreement, set to commence in January 2026, marks a notable shift as CVS Caremark replaces UnitedHealth's Optum Rx, which has managed CalPERS' prescription drug benefits since 2017.

NoahAI News7/17/2025

Thermo Fisher Expands US Manufacturing Capacity with Sanofi Plant Acquisition

Thermo Fisher Scientific has made a significant move to strengthen its drug manufacturing capabilities in the United States by acquiring a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey. The deal, announced on July 16, 2025, is part of Thermo Fisher's $2 billion investment pledge in US operations and is expected to close before the end of the year.

NoahAI News7/17/2025

Johnson & Johnson Boosts Financial Outlook on Strong Cardiovascular Device Sales

Johnson & Johnson (J&J) has raised its financial projections for 2025, buoyed by robust growth in its cardiovascular device business. The company's MedTech division reported impressive gains, particularly in cardiac device sales, despite facing challenges in the competitive pulsed field ablation market.

NoahAI News7/17/2025

«1...13 14 15...67 »